Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 7 Maj | 05:30:08 Europe / Stockholm

Svenska | English

BioStock

BioInvent International AB: BioStock: BioInvent secures FDA Fast Track Designation for BI-1808

2025-05-05 11:22:08

BioInvent has published its Q1 2025 interim report, outlining progress in its clinical programmes. Adding to the momentum, the FDA has granted Fast Track Designation to BI-1808 for the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, subtypes of cutaneous T-cell lymphoma. We reached out to BioInvent's CEO, Martin Welschof, for a comment.

Read the interview at biostock.se:

https://www.biostock.se/en/2025/05/bioinvent-secures-fda-fast-track-designation-for-bi-1808/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden